[{"orgOrder":0,"company":"Amolyt Pharma","sponsor":"PeptiDream","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AZP-3813","moa":"GHS receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Amolyt Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amolyt Pharma \/ PeptiDream","highestDevelopmentStatusID":"6","companyTruncated":"Amolyt Pharma \/ PeptiDream"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Adocia","sponsor":"Tonghua Dongbao Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Adocia \/ Tonghua Dongbao Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Adocia \/ Tonghua Dongbao Pharma"},{"orgOrder":0,"company":"Inserm","sponsor":"T.H.A.C.","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"ALF-5755","moa":"Regenerating human pro-islet peptide (REG3A)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Inserm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inserm \/ T.H.A.C.","highestDevelopmentStatusID":"6","companyTruncated":"Inserm \/ T.H.A.C."},{"orgOrder":0,"company":"Servier","sponsor":"Servier","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I","graph3":"Servier","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Servier \/ Servier","highestDevelopmentStatusID":"6","companyTruncated":"Servier \/ Servier"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : AZP-3813, a peptide GHR antagonist, is being developed as a potential treatment for acromegaly to be used in combination with somatostatin analogues (SSAs) for patients who do not adequately respond to SSAs alone.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 05, 2023

                          Lead Product(s) : AZP-3813

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : PeptiDream

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : AZP-3601, a long-acting parathyroid hormone (PTH) analog, normalizes blood calcium in thyroparathyroidectomized (TPTX) rats without causing deleterious changes in bone.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 16, 2022

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 1.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Insulin Glargine is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Insulin Glargine

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Tonghua Dongbao Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : AZP-3601, investigational therapeutic peptide designed to target specific conformation of PTH receptor safely produce sustained and stable levels of calcium in blood and manage symptoms of hypoparathyroidism, with goal of consequently preventing chronic ...

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          March 17, 2022

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : AZP-3601 is an investigational therapeutic peptide designed to target a specific conformation of the parathyroid hormone (PTH) receptor to safely produce sustained and stable levels of calcium in the blood and thereby manage the symptoms of hypoparathyro...

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          March 01, 2022

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : This acquisition strengthens the protection and the potential of the First in Class drug candidate of T.H.A.C which incorporates the active ingredient ALF-5755 for the treatment of Type 2 Diabetes Mellitus and severe complications.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          September 27, 2021

                          Lead Product(s) : ALF-5755

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : T.H.A.C.

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          08

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Amolyt will use the proceeds to advance its pipeline for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Undisclosed

                          September 16, 2021

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Sectoral Asset Management

                          Deal Size : $80.0 million

                          Deal Type : Series B Financing

                          blank

                          09

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Pramlintide, despite being the only drug approved as an adjunct to insulin in type 1 diabetes, is underused as it requires three additional daily injections in addition to the multiple injections of insulin.

                          Product Name : BC LisPram

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          June 29, 2021

                          Lead Product(s) : Insulin Lispro,Pramlintide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Aus. Peptide Conference
                          Not Confirmed
                          Aus. Peptide Conference
                          Not Confirmed

                          Details : Data from all cohorts from its Phase 1 Single Ascending Dose clinical trial evaluating AZP-3601, a parathyroid hormone (PTH) analog specifically designed for the treatment of hypoparathyroidism will be presented.

                          Product Name : Undisclosed

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 18, 2021

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank